Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph G Zinner

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2008
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.
Nature Biotechnology|December 24, 2002
Fingerprinting the circulating repertoire of antibodies from cancer patientsPaul J Mintz, Jeri Kim, Kim-Anh Do, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Oncogene|October 10, 2020
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancerHua Shen, Gao-Chan Wang, Xiang Li, et al.
Clinical Lung Cancer|April 28, 2006
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access programSheeba K Thomas, Frank V Fossella, Diane Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426Alex A Adjei, Sumithra J Mandrekar, Grace K Dy, et al.
Clinical Lung Cancer|May 7, 2021
Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian KentuckyChristine F Brainson, Bin Huang, Quan Chen, et al.
Molecular Cancer Therapeutics|September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsPrasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Oncotarget|March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusXiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2008
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.
Nature Biotechnology|December 24, 2002
Fingerprinting the circulating repertoire of antibodies from cancer patientsPaul J Mintz, Jeri Kim, Kim-Anh Do, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Oncogene|October 10, 2020
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancerHua Shen, Gao-Chan Wang, Xiang Li, et al.
Clinical Lung Cancer|April 28, 2006
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access programSheeba K Thomas, Frank V Fossella, Diane Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426Alex A Adjei, Sumithra J Mandrekar, Grace K Dy, et al.
Clinical Lung Cancer|May 7, 2021
Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian KentuckyChristine F Brainson, Bin Huang, Quan Chen, et al.
Molecular Cancer Therapeutics|September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsPrasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Oncotarget|March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimusXiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Pageof 5